Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antioxidants vs Combined Therapy with Clomiphene Citrate or FSH in Idiopathic OAT
NCT07862725Phase 4Not yet recruiting
- Sponsor
- Hamad Medical Corporation
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 4 trial of clomiphene, follicle-stimulating hormone in oligoasthenoteratozoospermia (OATS), sponsored by Hamad Medical Corporation. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
clomiphenefollicle-stimulating hormone
03
Conditions
oligoasthenoteratozoospermia (OATS)
Beyond the preview
Go deeper on NCT07862725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07862725.